Erythropoietin activates the phosphoinositide 3-kinase/Akt pathway in human melanoma cells

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Melanoma research

• Publication date

  2006-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/01.CMR.0000222594.60611.C3PMID 16845323
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy

  2005cited by this paper
• Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma.

  2005cited by this paper
• Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways.

  2005cited by this paper
• Comparison of the serum erythropoietin levels in chemotherapy-naive and cisplatin-treated cancer patients.

  2005cited by this paper
• Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma

  2005cited by this paper
• Akt activation is required at a late stage of insulin-induced GLUT4 translocation to the plasma membrane.

  2005cited by this paper
• Chemosensitization by erythropoietin through inhibition of the NF-κB rescue pathway

  2005cited by this paper
• The Akt-mTOR tango and its relevance to cancer.

  2005cited by this paper
• Functional erythropoietin autocrine loop in melanoma.

  2005cited by this paper
• The role of erythropoietin in regulating angiogenesis.

  2004cited by this paper
• Deregulated Akt3 Activity Promotes Development of Malignant Melanoma

  2004cited by this paper
• The erythropoietin receptor and its expression in tumor cells and other tissues.

  2004cited by this paper
• Erythropoietin modulates the anticancer activity of chemotherapeutic drugs in a murine lung cancer model.

  2004cited by this paper
• B-RAF is a therapeutic target in melanoma

  2004cited by this paper
• Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells.

  2004cited by this paper
• Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia‐reperfusion injury

  2004cited by this paper
• mTOR: a protein kinase switching between life and death.

  2004cited by this paper
• Antitumor Efficacy of Intermittent Treatment Schedules with the Rapamycin Derivative RAD001 Correlates with Prolonged Inactivation of Ribosomal Protein S6 Kinase 1 in Peripheral Blood Mononuclear Cells

  2004cited by this paper
• Can Erythropoietin Therapy Improve Survival?

  2004cited by this paper
• Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.

  2004cited by this paper
• Effect of haemopoietic growth factors on cancer cell lines and their role in chemosensitivity

  2004cited by this paper
• Autocrine erythropoietin signaling inhibits hypoxia-induced apoptosis in human breast carcinoma cells.

  2004cited by this paper
• Erythropoietin as an antiapoptotic, tissue-protective cytokine

  2004cited by this paper
• Erythropoietin receptor is expressed on adult rat dopaminergic neurons and erythropoietin is neurotrophic in cultured dopaminergic neuroblasts.

  2004cited by this paper
• An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection.

  2004cited by this paper
• Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer

  2004cited by this paper
• Erythropoietin regulates tumour growth of human malignancies.

  2003cited by this paper
• Targeting HIF-1 for cancer therapy

  2003cited by this paper
• A Novel Hypoxia-inducible Factor-independent Hypoxic Response Regulating Mammalian Target of Rapamycin and Its Targets*

  2003cited by this paper
• Erythropoietin as a critical component of breast cancer therapy: survival, synergistic, and cognitive applications.

  2003cited by this paper
• Regulation of Hypoxia-inducible Factor-1α Protein Level during Hypoxic Conditions by the Phosphatidylinositol 3-Kinase/Akt/Glycogen Synthase Kinase 3β Pathway in HepG2 Cells*

  2003cited by this paper
• Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression.

  2003cited by this paper
• Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling

  2003cited by this paper
• Reciprocal regulation of MelCAM and AKT in human melanoma

  2003cited by this paper
• Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo

  2003cited by this paper
• Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway.

  2003cited by this paper
• Human recombinant erythropoietin significantly improves tumor oxygenation independent of its effects on hemoglobin.

  2003cited by this paper
• Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells.

  2003cited by this paper
• A novel protective effect of erythropoietin in the infarcted heart.

  2003cited by this paper
• Phosphatidylinositol 3-Kinase/Akt Signaling Is Neither Required for Hypoxic Stabilization of HIF-1α nor Sufficient for HIF-1-dependent Target Gene Transcription*

  2002cited by this paper
• Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma

  2002cited by this paper
• Quantitation of the mRNA levels of Epo and EpoR in various tissues in the ovine fetus.

  2002cited by this paper
• Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury

  2002cited by this paper
• Functional Significance of Erythropoietin Receptor Expression in Breast Cancer

  2002cited by this paper
• A novel mutation in the erythropoietin receptor gene is associated with familial erythrocytosis.

  2002cited by this paper
• Erythropoietin and erythropoietin receptor expression in human cancer.

  2001cited by this paper
• Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-κB signalling cascades

  2001cited by this paper
• Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain

  2001cited by this paper
• Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades.

  2001cited by this paper
• Low doses of EPO activate MAP kinases but not JAK2-STAT5 in rat vascular smooth muscle cells.

  2001cited by this paper
• Erythropoietin receptor expression in human melanoma cells

  2000cited by this paper
• Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation.

  1999cited by this paper
• Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia.

  1998cited by this paper
• Erythropoietin and Erythropoietin Receptor in the Developing Human Central Nervous System

  1998cited by this paper
• Anemia in children with cancer is associated with decreased erythropoietic activity and not with inadequate erythropoietin production.

  1998cited by this paper
• Erythropoietin: Physiologic and Pharmacologic Aspects

  1997cited by this paper
• Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours

  1996cited by this paper
• Protein kinases in normal and transformed melanocytes

  1994cited by this paper
• A constitutively activated erythropoietin receptor stimulates proliferation and contributes to transformation of multipotent, committed nonerythroid and erythroid progenitor cells

  1994cited by this paper

• The Role of PI3K/AKT and MAPK Signaling Pathways in Erythropoietin Signalization

  2021cites this paper
• Anemia management in cancer patients with chronic kidney disease

  2019cites this paper
• No erythropoietin-induced growth is observed in non-small cell lung cancer cells.

  2017cites this paper
• The Biology of Melanoma

  2016cites this paper
• Systematic Review: The Association and Impact of Financial Conflicts of Interest in Basic Science Research

  2014cites this paper
• Phenotyping of Human Melanoma Cells Reveals a Unique Composition of Receptor Targets and a Subpopulation Co-Expressing ErbB4, EPO-R and NGF-R

  2014cites this paper
• Venous thromboembolism risk and erythropoiesis-stimulating agents for the treatment of cancer-associated anemia: a meta-analysis

  2013cites this paper
• Risk of venous thromboembolism with the erythropoiesisstimulating agents (ESAs) for the treatment of cancer-associated anemia: a meta-analysis of randomized control trials

  2013cites this paper
• Vaccinia virus-mediated expression of human erythropoietin in tumors enhances virotherapy and alleviates cancer-related anemia in mice.

  2013cites this paper
• Hematopoietic growth factors: Personalization of risks and benefits

  2012cites this paper
• The Role of Erythropoietin and its Receptor in Growth and Survival of non-small cell Lung Cancer cells

  2012cites this paper
• Risk of venous thromboembolism with the erythropoiesis-stimulating agents (ESAs) for the treatment of cancer-associated anemia: a meta-analysis of randomized control trials.

  2012cites this paper
• Long‐term prognostic impact of the use of erythropoietic‐stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib

  2011cites this paper
• Recombinant human erythropoietin promotes the acquisition of a malignant phenotype in head and neck squamous cell carcinoma cell lines in vitro

  2011cites this paper
• Erythropoietin Protects Intestinal Epithelial Barrier Function and Lowers the Incidence of Experimental Neonatal Necrotizing Enterocolitis*

  2011cites this paper
• Erythropoietin.

  2011cites this paper
• Promises and Pitfalls in Erythopoietin-Mediated Tissue Protection

  2011cites this paper
• Association between pharmaceutical support and basic science research on erythropoiesis-stimulating agents.

  2010cites this paper
• [Treatment with beta-erythropoietin in lung cancer--effectiveness and quality of life improvement in clinical practice].

  2010cites this paper
• Eritropoetin-béta-kezelés tüdőrákban – Hatékonyság és életminőség-javulás a klinikai gyakorlatban@@@Supportive treatment with beta-erythropoietin in patients with lung cancer – Clinical data analysis of quality of life and effectiveness

  2010cites this paper
• Neoplastic stem cells: current concepts and clinical perspectives.

  2010cites this paper
• Biological functions and therapeutic use of erythropoiesis‐stimulating agents: perplexities and perspectives

  2009cites this paper
• Erythropoietin-stimulating agents in oncology.

  2008cites this paper
• Erythropoiesis-Stimulating Agent Use in Cancer: Preclinical and Clinical Perspectives

  2008cites this paper
• Stimulating Erythropoiesis: Future Perspectives

  2008cites this paper
• Unraveling the Mystery of Erythropoietin-Stimulating Agents in Cancer Promotion.

  2008influential citation
• Role of Erythropoietin in Cancer-related Anaemia: A Double-edged Sword?

  2008cites this paper
• Erythropoietin in cancer: the new face of an old friend.

  2008cites this paper
• [Erythropoietic protein supportive treatment in small cell lung cancer].

  2008cites this paper
• Erythropoietin: new approaches to improved molecular designs and therapeutic alternatives.

  2008cites this paper
• Kissejte s tüdorákban szenve do betegek hatéko ny eritropoet ikus prote in ke zel ése - Saját tapasztalatok

  2008cites this paper
• Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.

  2008cites this paper
• Erythropoietin and Erythropoietin Receptor Coexpression Is Associated with Poor Survival in Stage I Non–Small Cell Lung Cancer

  2007cites this paper
• Wpływ leczenia rekombinowaną ludzką erytropoetyną (rnEPO) na dynamikę aktywacji i proliferacji limfocytów T CD4+ u chorych hemodializowanych i przewidzianych do przeszczepu nerki

  2007cites this paper
• BACKGROUND INFORMATION FOR ONCOLOGIC DRUGS ADVISORY COMMITTEE

  2007influential citation
• Mutant V600E BRAF Increases Hypoxia Inducible Factor-1α Expression in Melanoma

  2007cites this paper
• Does Erythropoietin Have a Dark Side? Epo Signaling and Cancer Cells

  2007cites this paper
• Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma.

  2007cites this paper
• Understanding the presence and function of erythropoietin receptors on cancer cells.

  2006cites this paper